Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | TNKS | O95271 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453351 | 0.73 | RXFP1 (0.49) | KMT2ANPC1RAB9ARAD52L3MBTL1 | |
| SCHEMBL5453198 | 0.72 | ATM (0.62) | KMT2ANPC1RAB9ARAD52ATM | |
| SCHEMBL13485788 | 0.71 | PDE5A (0.67) | PDE5ASIGMAR1TNKSPARP1TNKS2 | |
| SCHEMBL6461145 | 0.70 | SIGMAR1 (0.53) | PDE5ASIGMAR1TNKSPARP1TNKS2 | |
| SCHEMBL5460249 | 0.70 | KMT2A (0.65) | KMT2ANPC1RAB9AL3MBTL1ATM | |
| SCHEMBL5460132 | 0.68 | L3MBTL1 (0.62) | KMT2ANPC1RAB9AL3MBTL1ATM | |
| SCHEMBL1207853 | 0.68 | SIGMAR1 (0.56) | KMT2APDE5ASIGMAR1TNKSPARP1 | |
| SCHEMBL5458955 | 0.68 | KMT2A (0.63) | KMT2ANPC1RAB9AL3MBTL1ATM | |
| SCHEMBL15727649 | 0.68 | PDE5A (0.60) | PDE5ASIGMAR1 | |
| SCHEMBL503654 | 0.67 | SIGMAR1 (0.57) | PDE5AATMSIGMAR1TNKSPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | KMT2A 4785/4885NPC1 2627/4885RAB9A 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.